- Page 1 and 2:
2011 WHO Collaborating Centre for D
- Page 3 and 4:
ISSN 1726-4898 ISBN 978-82-8082-438
- Page 5 and 6:
Previous editions: 1990: Guidelines
- Page 7 and 8:
Staff of the Centre Christian Berg,
- Page 9 and 10:
8 D. Principles for reviewing and c
- Page 11 and 12:
I. INTRODUCTION A. History of the A
- Page 13 and 14:
- To organize training courses in t
- Page 15 and 16:
It is open to anyone with a legitim
- Page 17 and 18:
B. Inclusion and exclusion criteria
- Page 19 and 20:
If a new substance fits in both a c
- Page 21 and 22:
Example: N02BA71 - acetylsalicylic
- Page 23 and 24:
achieved. The harmonisation process
- Page 25 and 26:
- For some groups of medicinal prod
- Page 27 and 28:
For all combination products where
- Page 29 and 30:
- Liquid preparations for inhalatio
- Page 31 and 32:
Further reviews of DDDs After the f
- Page 33 and 34:
linked to each medicinal product on
- Page 35 and 36:
Use of the ATC/DDD system allows st
- Page 37 and 38:
The WHO Collaborating Centre for In
- Page 39 and 40:
It should be emphasised that assign
- Page 41 and 42:
- If no objections are received, th
- Page 43 and 44:
In order to include proposals for A
- Page 45 and 46:
considered as a guideline since the
- Page 47 and 48:
List of DDDs for combined products
- Page 49 and 50:
ATC SYSTEM MAIN GROUPS The main gro
- Page 51 and 52:
A08 ANTIOBESITY PREPARATIONS, EXCL.
- Page 53 and 54:
A01AC Corticosteroids for local ora
- Page 55 and 56:
A02AF Antacids with antiflatulents
- Page 57 and 58:
56 combination will, together with
- Page 59 and 60:
58 The classification at the 5th le
- Page 61 and 62:
A03EA Antispasmodics, psycholeptics
- Page 63 and 64:
A06 LAXATIVES A06A LAXATIVES 62 Lax
- Page 65 and 66:
A06AG Enemas 64 All enemas and laxa
- Page 67 and 68:
A07C ELECTROLYTES WITH CARBOHYDRATE
- Page 69 and 70:
A08 ANTIOBESITY PREPARATIONS, EXCL.
- Page 71 and 72:
A10B BLOOD GLUCOSE LOWERING DRUGS,
- Page 73 and 74:
72 In A11AA04 only trace elements a
- Page 75 and 76:
74 The DDDs are based on prophylaxi
- Page 77 and 78:
76 classified in this group. Even c
- Page 79 and 80:
78 Tonics are classified in A13. Th
- Page 81 and 82:
A12CC Magnesium A12CD Fluoride A12C
- Page 83 and 84:
A16 OTHER ALIMENTARY TRACT AND META
- Page 85 and 86:
B BLOOD AND BLOOD FORMING ORGANS B0
- Page 87 and 88:
B02 ANTIHEMORRHAGICS B02A ANTIFIBRI
- Page 89 and 90:
B03AA Iron bivalent, oral preparati
- Page 91 and 92:
90 The DDDs are based on maintenanc
- Page 93 and 94:
B05C IRRIGATING SOLUTIONS 92 In thi
- Page 96 and 97:
C CARDIOVASCULAR SYSTEM C01 CARDIAC
- Page 98 and 99:
C CARDIOVASCULAR SYSTEM C01 CARDIAC
- Page 100 and 101:
C01C CARDIAC STIMULANTS EXCL. CARDI
- Page 102 and 103:
C01E OTHER CARDIAC PREPARATIONS Thi
- Page 104 and 105:
Combinations with other antihyperte
- Page 106 and 107:
C02DD Nitroferricyanide derivatives
- Page 108 and 109:
C02LX Other antihypertensives and d
- Page 110 and 111:
C03BX Other low-ceiling diuretics A
- Page 112 and 113:
C04AC Nicotinic acid and derivative
- Page 114 and 115:
C05BA Heparins or heparinoids for t
- Page 116 and 117:
C07BG Alpha and beta blocking agent
- Page 118 and 119:
Combinations with ACE inhibitors ar
- Page 120 and 121:
C09BB ACE inhibitors and calcium ch
- Page 122:
C10B LIPID MODIFYING AGENTS, COMBIN
- Page 125 and 126:
D10 ANTI-ACNE PREPARATIONS A Anti-a
- Page 127 and 128:
D01AC Imidazole and triazole deriva
- Page 129 and 130:
D02B PROTECTIVES AGAINST UV-RADIATI
- Page 131 and 132:
D04AX Other antipruritics 130 This
- Page 133 and 134: D06AX Other antibiotics for topical
- Page 135 and 136: D07BB Corticosteroids, moderately p
- Page 137 and 138: D08AD Boric acid products 136 Weak
- Page 139 and 140: D10AB Preparations containing sulfu
- Page 141 and 142: D11AX Other dermatologicals 140 Thi
- Page 143 and 144: G GENITO URINARY SYSTEM AND SEX HOR
- Page 145 and 146: G02 OTHER GYNECOLOGICALS 144 Analge
- Page 147 and 148: 146 Lisuride tablets in high streng
- Page 149 and 150: G03AD Emergency contraceptives 148
- Page 151 and 152: G03CX Other estrogens 150 Tibolone
- Page 153 and 154: 152 package which is intended for o
- Page 155 and 156: G04BC Urinary concrement solvents 1
- Page 158 and 159: H SYSTEMIC HORMONAL PREPARATIONS, E
- Page 160 and 161: The DDDs are based on the treatment
- Page 162 and 163: H02A CORTICOSTEROIDS FOR SYSTEMIC U
- Page 164 and 165: H04 PANCREATIC HORMONES H04A GLYCOG
- Page 166 and 167: J ANTIINFECTIVES FOR SYSTEMIC USE J
- Page 168 and 169: J01 ANTIBACTERIALS FOR SYSTEMIC USE
- Page 170 and 171: inhibitor are classified at a separ
- Page 172 and 173: J01EA Trimethoprim and derivatives
- Page 174 and 175: J01MA Fluoroquinolones Flumequine i
- Page 176 and 177: The parenteral DDD for fosfomycin i
- Page 178 and 179: J04B DRUGS FOR TREATMENT OF LEPRA J
- Page 180 and 181: The DDD of oseltamivir is based on
- Page 182 and 183: 5th level, while other monovalent v
- Page 186 and 187: L ANTINEOPLASTIC AND IMMUNOMODULATI
- Page 188 and 189: L01B ANTIMETABOLITES L01BA Folic ac
- Page 190 and 191: L02A HORMONES AND RELATED AGENTS An
- Page 192: The DDDs are mainly based on prophy
- Page 195 and 196: M MUSCULO-SKELETAL SYSTEM M01 ANTII
- Page 197 and 198: 196 The DDD for glucosamine refers
- Page 199 and 200: 198 Combined preparations containin
- Page 201 and 202: M03C MUSCLE RELAXANTS, DIRECTLY ACT
- Page 203 and 204: M05BX Other drugs affecting bone st
- Page 205 and 206: N NERVOUS SYSTEM N01 ANESTHETICS 20
- Page 207 and 208: N01BC Esters of benzoic acid N01BX
- Page 209 and 210: 208 The DDDs are based on approved
- Page 211 and 212: 210 This means that a product conta
- Page 213 and 214: 212 Tolfenamic acid, see M01AG - Fe
- Page 215 and 216: 214 Benzodiazepines mainly used as
- Page 217 and 218: N05A ANTIPSYCHOTICS 216 This group
- Page 219 and 220: 218 The parenteral DDD for chlordia
- Page 221 and 222: N05CM Other hypnotics and sedatives
- Page 223 and 224: N06C PSYCHOLEPTICS AND PSYCHOANALEP
- Page 225 and 226: N07CA Antivertigo preparations 224
- Page 227 and 228: P ANTIPARASITIC PRODUCTS, INSECTICI
- Page 229 and 230: P01BC Methanolquinolines 228 Combin
- Page 231 and 232: P02 ANTHELMINTICS 230 The anthelmin
- Page 233 and 234: P03A ECTOPARASITICIDES, INCL. SCABI
- Page 235 and 236:
R RESPIRATORY SYSTEM 234 Inhaled an
- Page 237 and 238:
R01B NASAL DECONGESTANTS FOR SYSTEM
- Page 239 and 240:
238 The DDDs for inhalation aerosol
- Page 241 and 242:
R03C ADRENERGICS FOR SYSTEMIC USE 2
- Page 243 and 244:
242 Fixed DDDs are assigned for com
- Page 245 and 246:
R05X OTHER COLD COMBINATION PREPARA
- Page 247 and 248:
R07AA Lung surfactants 246 This gro
- Page 249 and 250:
S SENSORY ORGANS 248 A formulation
- Page 251 and 252:
S01CB Corticosteroids/antiinfective
- Page 253 and 254:
S01H LOCAL ANESTHETICS 252 This gro
- Page 255 and 256:
S02A ANTIINFECTIVES 254 This group
- Page 257 and 258:
S03B CORTICOSTEROIDS 256 This group
- Page 259 and 260:
V10 THERAPEUTIC RADIOPHARMACEUTICAL
- Page 261 and 262:
260 Silibinin, which is also used i
- Page 263 and 264:
V04 DIAGNOSTIC AGENTS V04B URINE TE
- Page 265 and 266:
V06DX Other combinations of nutrien
- Page 267 and 268:
V08B X-RAY CONTRAST MEDIA, NON-IODI
- Page 269 and 270:
268 V09E - Respiratory system. Tech
- Page 271 and 272:
V09H INFLAMMATION AND INFECTION DET
- Page 273 and 274:
272 Iobenguane ( 131 I) in low dose
- Page 275 and 276:
DDDs per 100 bed days Applied when
- Page 278:
ANNEX I
- Page 281 and 282:
Status concerning Marketing Authori
- Page 284 and 285:
ORDER FORM ATC/DDD PUBLICATIONS 201
- Page 286:
WHO Collaborating Centre for Drug S